Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: Drug-discovery strategies

No abstract is available for this paper.

• Publication year

  2009

• Venue

  International Review of Psychiatry

• Publication date

  2009-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1080/09540260902782778PMID 19367506PMCID PMC5531754
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2-RRM2 axis in KRASG12C-mutant lung cancer

  2019influential reference
• Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?

  2009cited by this paper
• Spinal Microglial and Perivascular Cell Cannabinoid Receptor Type 2 Activation Reduces Behavioral Hypersensitivity without Tolerance after Peripheral Nerve Injury

  2008cited by this paper
• Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.

  2008cited by this paper
• A Saturated N‐Acylethanolamine Other than N‐Palmitoyl Ethanolamine with Anti‐inflammatory Properties: a Neglected Story…

  2008cited by this paper
• CB receptor ligands from plants.

  2008cited by this paper
• Genetic and pharmacological manipulations of the CB1 receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice

  2008cited by this paper
• Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non‐cannabinoid receptor‐mediated mechanisms

  2008cited by this paper
• Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.

  2008cited by this paper
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

  2008cited by this paper
• The hope and fear of rimonabant.

  2008cited by this paper
• Enzymatic pathways that regulate endocannabinoid signaling in the nervous system.

  2008cited by this paper
• Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism.

  2008cited by this paper
• Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia.

  2008cited by this paper
• Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice.

  2008cited by this paper
• The Novel Cannabinoid CB1 Receptor Neutral Antagonist AM4113 Suppresses Food Intake and Food-Reinforced Behavior but Does not Induce Signs of Nausea in Rats

  2008cited by this paper
• Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors*

  2008cited by this paper
• Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.

  2008cited by this paper
• CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications.

  2008cited by this paper
• The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats.

  2008cited by this paper
• Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis.

  2008influential reference
• Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor.

  2008cited by this paper
• Paracetamol (Acetaminophen): mechanisms of action

  2008cited by this paper
• The endocannabinoid system: emotion, learning and addiction

  2008cited by this paper
• Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.

  2008cited by this paper
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin

  2008influential reference
• Cannabis and psychiatric disorders: it is not only addiction

  2008cited by this paper
• Adverse effects of medical cannabinoids: a systematic review

  2008cited by this paper
• Endocannabinoids and the regulation of their levels in health and disease

  2007cited by this paper
• Endocannabinoids and psychopathology: the therapy inside.

  2007cited by this paper
• Cannabinoids Elicit Antidepressant-Like Behavior and Activate Serotonergic Neurons through the Medial Prefrontal Cortex

  2007cited by this paper
• Endocannabinoid Enhancement Protects against Kainic Acid-Induced Seizures and Associated Brain Damage

  2007cited by this paper
• CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents.

  2007cited by this paper
• Cannabidiol – Recent Advances

  2007cited by this paper
• Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals.

  2007cited by this paper
• The Endogenous Cannabinoid Anandamide Produces δ-9-Tetrahydrocannabinol-Like Discriminative and Neurochemical Effects That Are Enhanced by Inhibition of Fatty Acid Amide Hydrolase but Not by Inhibition of Anandamide Transport

  2007cited by this paper
• Meta‐analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences

  2007cited by this paper
• The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.

  2007cited by this paper
• Targeted modulators of the endogenous cannabinoid system: Future medications to treat addiction disorders and obesity

  2007cited by this paper
• GPR55: a new member of the cannabinoid receptor clan?

  2007cited by this paper
• Acute and Non-acute Effects of Cannabis on Brain Functioning and Neuropsychological Performance

  2007cited by this paper
• Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions.

  2007cited by this paper
• Fatty Acid Amide Hydrolase: From Characterization to Therapeutics

  2007cited by this paper
• Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.

  2007influential reference
• Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers.

  2007cited by this paper
• Blocking the Cannabinoid Receptors: Drug Candidates and Therapeutic Promises

  2007cited by this paper
• Allosterism and cannabinoid CB(1) receptors: the shape of things to come.

  2007cited by this paper
• Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models

  2006cited by this paper
• Pharmacological Characterization of Endocannabinoid Transport and Fatty Acid Amide Hydrolase Inhibitors

  2006cited by this paper
• Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats.

  2006cited by this paper
• Cannabinoid receptors and endocannabinoids: Evidence for new players

  2006cited by this paper
• The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases.

  2006influential reference
• Anxiolytic-Like Properties of the Anandamide Transport Inhibitor AM404

  2006cited by this paper
• Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes.

  2005cited by this paper
• Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation

  2005cited by this paper
• Molecular Characterization of N-Acylethanolamine-hydrolyzing Acid Amidase, a Novel Member of the Choloylglycine Hydrolase Family with Structural and Functional Similarity to Acid Ceramidase*

  2005cited by this paper
• Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes.

  2005cited by this paper
• Characterization of the Fatty Acid Amide Hydrolase Inhibitor Cyclohexyl Carbamic Acid 3′-Carbamoyl-biphenyl-3-yl Ester (URB597): Effects on Anandamide and Oleoylethanolamide Deactivation

  2005cited by this paper
• Adamantyl cannabinoids: a novel class of cannabinergic ligands.

  2005cited by this paper
• The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids

  2005cited by this paper
• Natural cannabinoids: templates for drug discovery.

  2005influential reference
• The endocannabinoid system and its therapeutic exploitation

  2004cited by this paper
• Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist

  2004cited by this paper
• Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle.

  2004cited by this paper
• Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors.

  2004influential reference
• CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?

  2003cited by this paper
• Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease

  2003cited by this paper
• Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS

  2003influential reference
• Anandamide hydrolysis: a new target for anti-anxiety drugs?

  2003cited by this paper
• Oxidative metabolism of endocannabinoids.

  2002cited by this paper
• N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.

  2002cited by this paper
• The palmitoylethanolamide family: a new class of anti-inflammatory agents?

  2002cited by this paper
• Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands.

  2001cited by this paper
• 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor

  2001cited by this paper
• CB2 cannabinoid receptor‐mediated peripheral antinociception

  2001cited by this paper
• Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404.

  2000cited by this paper
• Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374).

  1999cited by this paper
• The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?

  1999cited by this paper
• Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1).

  1999cited by this paper
• Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses.

  1999cited by this paper
• Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors.

  1999cited by this paper
• The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes.

  1998cited by this paper
• Imaging the Brain Marijuana Receptor: Development of a Radioligand that Binds to Cannabinoid CB1 Receptors In Vivo

  1998cited by this paper
• Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.

  1998influential reference
• Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.

  1998cited by this paper
• SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

  1998cited by this paper
• Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor.

  1997cited by this paper
• Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors.

  1997cited by this paper
• AM630, a competitive cannabinoid receptor antagonist.

  1995cited by this paper
• Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids.

  1995cited by this paper
• Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.

  1995cited by this paper
• (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.

  1994cited by this paper
• SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

  1994cited by this paper
• Antinociceptive (aminoalkyl)indoles.

  1991cited by this paper
• Pharmacological evaluation of halogenated delta 8-THC analogs.

  1991influential reference
• The molecular basis of cannabinoid activity.

  1990cited by this paper
• Cannabinoid receptor localization in brain.

  1990cited by this paper
• Enantiomeric cannabinoids: stereospecificity of psychotropic activity

  1988cited by this paper
• FATTY ACID AMIDES OF ETHANOLAMINE IN MAMMALIAN TISSUES.

  1965cited by this paper

• LY-2183240 enhances reward-seeking behavior with inducing neuronal excitation and early apoptosis in mouse

  2024cites this paper
• Roles of the Cannabinoid System in the Basal Ganglia in Parkinson’s Disease

  2022cites this paper
• Effects of repeated lysergic acid diethylamide (LSD) on the mouse brain endocannabinoidome and gut microbiome

  2022cites this paper
• Occurrence of Morpholine in Central Nervous System Drug Discovery

  2021cites this paper
• International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management.

  2021cites this paper
• Endocannabinoids Interact With the Dopaminergic System to Increase Sexual Motivation: Lessons From the Sexual Satiety Phenomenon

  2019cites this paper
• The Molecular Basis of Cannabinoid Activity: Application to Therapeutics Design and Discovery for Cannabis Use Disorders

  2018cites this paper
• Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.

  2017cites this paper
• The characterization of the human monoacylglycerol lipase using mutagenesis, enzyme kinetics and NMR spectroscopy

  2017cites this paper
• Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys

  2016cites this paper
• Specific Inter-residue Interactions as Determinants of Human Monoacylglycerol Lipase Catalytic Competency

  2015cites this paper
• Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection

  2015cites this paper
• Cannabis Use Disorders

  2014cites this paper
• Ligand-assisted protein structure characterization as a method for exploring the binding and functional motifs of ligands on the CB2 cannabinoid receptor 2

  2014cites this paper
• Analysis of the structure and function of endocannabinoid-hydrolyzing enzymes using biophysical and nanomedical techniques

  2014cites this paper
• Membrane phospholipid bilayer as a determinant of monoacylglycerol lipase kinetic profile and conformational repertoire

  2013cites this paper
• The neuroprotective role of endocannabinoids against chemical‐induced injury and other adverse effects

  2013cites this paper
• The role of endocannabinoids in pain modulation

  2013cites this paper
• Novel Mechanisms and Therapeutics in the Treatment for Cancer-Induced Bone Pain

  2013influential citation
• Multivalent Cathepsin Inhibitor, VBY-825, Attenuates Breast-Induced Bone Cancer Remodelling and Pain

  2013cites this paper
• Ethnobotanical treatment strategies against Alzheimer's disease.

  2012cites this paper
• The endocannabinoid transport inhibitor AM404 differentially modulates recognition memory in rats depending on environmental aversiveness

  2012cites this paper
• Equipotent Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase – Dual Targets of the Endocannabinoid System to Protect against Seizure Pathology

  2012cites this paper
• Human Cannabinoid 1 GPCR C-Terminal Domain Interacts with Bilayer Phospholipids to Modulate the Structure of its Membrane Environment

  2011cites this paper
• Human Cannabinoid 2 GPCR Ligand-interaction Landscape: Cysteine Residues Critical to Biarylpyrazole Antagonist Binding Motif and Receptor Modulation

  2011influential citation
• The Role of Phytochemicals in the Treatment and Prevention of Dementia

  2011cites this paper
• A New Generation Fatty Acid Amide Hydrolase Inhibitor Protects Against Kainate-Induced Excitotoxicity

  2011cites this paper
• Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats

  2011cites this paper
• Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation.

  2011cites this paper
• Pharmacological and psychosocial interventions for cannabis use disorders: Intervenções farmacológica e psicossocial para os distúrbios de uso da cannabis

  2010cites this paper
• Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.

  2010cites this paper
• Identification by nuclear magnetic resonance spectroscopy of an active-site hydrogen-bond network in human monoacylglycerol lipase (hMGL): implications for hMGL dynamics, pharmacological inhibition, and catalytic mechanism.

  2010cites this paper
• hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.

  2010cites this paper
• [Pharmacological and psychosocial interventions for cannabis use disorders].

  2010cites this paper
• Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects.

  2010cites this paper
• Pharmacological and psychosocial interventions for cannabis use disorders

  2010cites this paper
• Structural biology of human cannabinoid receptor-2 helix 6 in membrane-mimetic environments.

  2009cites this paper